Customer Support: +44 (0)203 327 3140

Your region & currency

United Kingdom English(GB)

Pricing in GBP £

Local sites

  • Shopping Cart
    There are no items in your cart

We noticed you are browsing from United States. Switch to our United States site for local pricing in USD.

Dismiss alert

AAMI TIR48 : 2015

Superseded

Superseded

View Superseded by

QUALITY MANAGEMENT SYSTEM (QMS) RECOMMENDATIONS ON THE APPLICATION OF THE U.S. FDAS CGMP FINAL RULE ON COMBINATION PRODUCTS

Available format(s)

PDF

Language(s)

English

Published date

01-01-2015

Superseded date

21-05-2021

Superseded by

AAMI TIR48:2015(R2021)

£201.74
Excluding VAT
Summarise this standard

Glossary of equivalent standards
Committee representation
Introduction
1 Scope
2 Applying CGMPs in Accord with FDA's Final Rule
  for Combination Products (21 CFR Part 4)
3 Considerations in transitioning
  to 'Streamlined Approach'
4 Application of Design Controls and
  Management for a Combination Product
Annex A - Terminology
Bibliography

Gives recommendations on the application of CGMPs for drugs, devices, biologics, and human cells, tissues, and cellular and tissue based products during development and marketing of combination products (drug-device, biologic-device, drug-biologic, or drug-device-biologic), in accordance with the FDA's final rule (21 CFR Part 4; 78 FR 4307, 2013-hereafter 'The Rule' or 'FDA's Final Rule').

DocumentType
Standard
Pages
28
PublisherName
Association for the Advancement of Medical Instrumentation
Status
Superseded
SupersededBy

⚠

A newer version of this standard is available.

View Current Edition
£201.74
Excluding VAT